Back to Search
Start Over
Diosgenin attenuates tumor growth and metastasis in transgenic prostate cancer mouse model by negatively regulating both NF-κB/STAT3 signaling cascades.
- Source :
-
European journal of pharmacology [Eur J Pharmacol] 2021 Sep 05; Vol. 906, pp. 174274. Date of Electronic Publication: 2021 Jun 17. - Publication Year :
- 2021
-
Abstract
- Prostate cancer (PCa) is a common disease among men especially in the old age. The deregulated activation of oncogenic and pro-survival transcription factors has been linked with tumor progression in PCa patients. The consequence of diosgenin treatment on NF-κB/STAT3 activation in PCa cells as well as transgenic mouse model was determined. We also validated the hypothesis of targeting these transcription factors using in silico proteomics simulation model. Diosgenin abrogated NF-κB/STAT3 activation and this action was caused as a result of suppression of protein kinases and reporter gene activity that led to a substantial reduction in the expression of various tumorigenic gene products. In vivo, diosgenin (2% w/w) when mixed in diet and fed to mice abrogated tumor progression in transgenic mice. Diosgenin was also detected in serum and was well absorbed orally. Overall, our data highlights the promising efficacy of diosgenin in PCa therapy.<br /> (Copyright © 2021 Elsevier B.V. All rights reserved.)
- Subjects :
- Administration, Oral
Animals
Cell Line, Tumor
Computer Simulation
Diosgenin therapeutic use
Disease Models, Animal
Drug Screening Assays, Antitumor
Humans
Male
Mice
Mice, Transgenic
NF-kappa B metabolism
Prostatic Neoplasms genetics
Prostatic Neoplasms pathology
Proteomics
STAT3 Transcription Factor metabolism
Signal Transduction drug effects
Diosgenin pharmacology
Prostatic Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0712
- Volume :
- 906
- Database :
- MEDLINE
- Journal :
- European journal of pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 34146587
- Full Text :
- https://doi.org/10.1016/j.ejphar.2021.174274